Skip to content

Teriparatide

Also called Forteo, PTH(1-34)

Subcutaneous (under the skin)Product label

Research reference

Product label

Teriparatide ready-filled device

20 mcg once daily using the supplied device

Course individualized; beyond 2 lifetime years only when high fracture risk remains or returns

Teriparatide product label ↗

When results may show

When change was measured
Bone health, calcium and adverse effects require clinical review. The pen's 28 daily doses are a device supply, not the whole course.
When to assess
Course individualized; beyond 2 lifetime years only when high fracture risk remains or returns
Conditions and limitations
Specified adults with osteoporosis at high fracture risk. Exact ready-filled product only; do not mix, transfer to another pen, or copy this schedule into an unidentified powder vial.
When to stop
Use the exact product's clinical monitoring and stopping instructions. A supply interval is not a stop date; severe or persistent reactions need prompt clinical review.

Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.

Key properties

Formula
C181H291N55O51S2
Mol. weight
4,117.8 Da
CAS
52232-67-4
PubChem CID
16133850

Sequence (one-letter)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF

Vial arithmetic

Published research contexts for Teriparatide describe 20–40 mcg per administration. Descriptive only, not a recommendation.

Modelled level — every day

1× is the peak after a single dose.

Steady-state peak
1.00× single dose

Read off the modelled curve, not an even-interval formula

Time to steady state
5hours

About five half-lives

Administrations
7/ week

Where these numbers come from

  • Teriparatide product labelExact ready-filled product only; do not mix, transfer to another pen, or copy this schedule into an unidentified powder vial.

Next steps